SOUTH SAN FRANCISCO, Calif. (TheStreet) -- U.S. regulators approved Monday a new drug from Roche and Curis that treats a common but advanced form of skin cancer. The new drug, Erivedge, is the first therapy approved by the U.S. Food and Drug Administration for the treatment of advanced basal cell cancer. The FDA approved Erivedge well ahead of the drug's expected March 8 approval decision date ...